High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma

scientific article published on September 2016

High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/AJCP/AQW110
P698PubMed publication ID27543975

P2093author name stringChen Lin
Jian Gao
Yun Xu
Lie Wang
Ruohan Wang
Qiaojia Huang
Daiyong Wang
Zaizhong Zhang
Shaoquan Chen
Xiaohuang Tu
P2860cites workBenefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysisQ37742318
Roles of VEGF-A signalling in development, regeneration, and tumoursQ38212662
Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical CancerQ41328969
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).Q41643156
A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancerQ42224250
Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.Q51617107
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.Q54291995
HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.Q54551877
Global cancer statisticsQ22241238
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionQ28215716
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesisQ29547178
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyQ29620647
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II studyQ31081052
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junctionQ33380002
Targeted inhibition of VEGF receptor 2: an update on ramucirumabQ34040956
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Q35863874
Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitroQ37370761
Molecular basis of therapeutic approaches to gastric cancerQ37386372
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectendotheliumQ111140
adenocarcinomaQ356033
P304page(s)278-288
P577publication date2016-09-01
P1433published inAmerican Journal of Clinical PathologyQ15750224
P1476titleHigh Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma
P478volume146